Zymo Melanoma Drug Shrinks Tumors

Xconomy Seattle — 

ZymoGenetics, the Seattle biotech company, said today that one of its experimental cancer drugs that it is seeking to outlicense showed an ability to shrink tumors in a clinical trial. Interim results from a trial of 24 patients with metastatic melanoma—a form of skin cancer that has spread through the body and is difficult to treat—found that seven patients on Zymo’s IL-21 had their tumors shrink by at least 25 percent, and eight people had their disease stabilize.